Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion

Eur J Neurosci. 2006 Jul;24(2):520-6. doi: 10.1111/j.1460-9568.2006.04920.x. Epub 2006 Jul 12.

Abstract

Transient ischemia has been shown to damage the basal lamina of the cerebral microvasculature. Other studies proved statins to be beneficial to non-cerebral microvessels. The aim of this study was to determine whether pravastatin pretreatment ameliorates microvascular basal lamina damage following transient ischemia. Using the suture model, we subjected 15 rats to focal ischemia (3 h) and reperfusion (24 h). Rats received pravastatin (20 mg/kg/day) or saline for 4 weeks prior to the experiment. The outcome was determined by a behavior test and the infarct size. Collagen type IV, a marker for an intact basal lamina, and hemoglobin extravasation were measured by Western blot analysis. A ratio (in percentage) between ischemic and contralateral hemispheres was calculated. Pravastatin pretreatment resulted in a significantly better neurological outcome and reduced infarct size (15 +/- 0.5 and 59 +/- 10 mm(3), respectively) compared with controls (12.25 +/- 0.4 and 167 +/- 13 mm(3), respectively, P < 0.01 for both). In controls, loss of collagen type IV was seen in the basal ganglia and in the cortex (43 +/- 4 and 64 +/- 5%, respectively). Pravastatin prevented significant collagen loss (basal ganglia: 106 +/- 17%; cortex: 112 +/- 14%, P < 0.01 for both) and significantly reduced the hemoglobin extravasation compared with controls in the basal ganglia (198 +/- 49 vs. 553 +/- 47%, P < 0.01). Pravastatin pretreatment resulted in a reduction of microvascular basal lamina damage and hemoglobin extravasation following transient ischemia. Pravastatin seems to protect the cerebral microvascular system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Basement Membrane / drug effects
  • Basement Membrane / pathology
  • Basement Membrane / physiopathology
  • Biomarkers / metabolism
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / pathology
  • Blood-Brain Barrier / physiopathology
  • Cerebral Arterial Diseases / drug therapy*
  • Cerebral Arterial Diseases / metabolism
  • Cerebral Arterial Diseases / physiopathology
  • Cerebral Arteries / drug effects*
  • Cerebral Arteries / pathology
  • Cerebral Arteries / physiopathology
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / metabolism
  • Cerebral Infarction / physiopathology
  • Collagen Type IV / drug effects
  • Collagen Type IV / metabolism
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Down-Regulation / physiology
  • Hemoglobins / metabolism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperemia / drug therapy
  • Hyperemia / etiology
  • Hyperemia / physiopathology
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / metabolism
  • Ischemic Attack, Transient / physiopathology
  • Male
  • Microcirculation / drug effects*
  • Microcirculation / pathology
  • Microcirculation / physiopathology
  • Pravastatin / pharmacology*
  • Pravastatin / therapeutic use
  • Rats
  • Rats, Wistar
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / physiopathology

Substances

  • Biomarkers
  • Collagen Type IV
  • Hemoglobins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin